OTC Obesity - Portugal

Date: March 22, 2010
Pages: 32
Price:
US$ 990.00
Publisher: Euromonitor International Ltd
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O34C2470E37EN
Leaflet:

Download PDF Leaflet

Value sales of OTC obesity in Portugal, comprised exclusively of the Alli brand, represented EUR2 million in 2009. In fact, Alli the active ingredient of which is Oristat, was switched to be available in pharmacies and parapharmacies during the review period. Consumer receptivity to this new OTC medicine was very good, as to lose weight Portuguese consumers are willing to try all types of novelties, particularly those which benefit from word-of-mouth recommendations.

Euromonitor International's OTC Obesity Products in Portugal report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Consumer Health industry;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
OTC Obesity in Portugal
Euromonitor International
March 2010

LIST OF CONTENTS AND TABLES

Executive Summary
Consumer Healthcare Value Sales Affected by Adverse Economic Climate
Faster Growth Boosted by Advertising, Innovation and Interest in Healthy Living
Multinationals Led Consumer Healthcare
Parapharmacies and Internet Channels Gain Some More Ground
Modest Value Growth Expected Over the Forecast Period
Key Trends and Developments
Unfavourable Economic Climate Inhibits Stronger Value Growth
Rising Obesity Rates Stimulate Sales of OTC Obesity and Slimming Products
Ageing Population Will Boost Sales Over the Forecast Period
Tobacco Ban in Public Areas Stimulates Sales of Nrt Smoking Cessation Aids
Investments in Advertising and New Products Prove To Be Successful Strategies
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Consumer Health Company Shares by Value 2005-2009
  Table 6 Consumer Health Brand Shares by Value 2006-2009
  Table 7 Penetration of Private Label by Sector 2004-2009
  Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
  Summary 1 OTC Healthcare Switches 2007-2009
Definitions
  Summary 2 Research Sources
Coutinho & Alexandre Lda
Strategic Direction
Key Facts
  Summary 3 Coutinho & Alexandre Lda: Key Facts
  Summary 4 Coutinho & Alexandre Lda: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 5 Coutinho & Alexandre Lda: Competitive Position 2009
Distrifa- Soluções De Saude Lda
Strategic Direction
Key Facts
  Summary 6 Distrifa- Soluções de Saude Lda: Key Facts
Company Background
Production
Competitive Positioning
  Summary 7 Distrifa- Soluções de Saude Lda: Competitive Position 2009
Laboratorio J Neves, Lda
Strategic Direction
Key Facts
  Summary 8 Laboratorio J Neves Lda: Key Facts
  Summary 9 Laboratorio J Neves Lda: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 10 Laboratorio J Neves Lda: Competitive Position 2009
Laboratório Medinfar Produtos Farmacêuticos SA
Strategic Direction
Key Facts
  Summary 11 Laboratório Medinfar Produtos Farmacêuticos SA: Key Facts
Company Background
Production
Competitive Positioning
  Summary 12 Laboratório Medinfar Produtos Farmacêuticos SA: Competitive Position 2009
Natiris-centro Dietetico Lda
Strategic Direction
Key Facts
Company Background
Production
Competitive Positioning
  Summary 14 Natiris-Centro Dietético Lda: Competitive Position 2009
Trends
Category Data
  Table 12 Sales of OTC Obesity: Value 2009
  Table 13 OTC Obesity Company Shares by Value 2005-2009
  Table 14 OTC Obesity Brand Shares by Value 2006-2009
  Table 15 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 16 Forecast Sales of OTC Obesity: % Value Growth 2009-2014
Skip to top


OTC Obesity - Australia US$ 990.00 Jun, 2010 · 33 pages
OTC Obesity - Austria US$ 990.00 Apr, 2010 · 31 pages
OTC Obesity - Denmark US$ 990.00 Apr, 2010 · 29 pages
OTC Obesity - France US$ 990.00 Apr, 2010 · 49 pages
OTC Obesity - Greece US$ 990.00 Mar, 2010 · 33 pages

Ask Your Question

OTC Obesity - Portugal
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: